Stock Markets July 9, 2026 02:06 PM

Stocks Swing Across Market Caps as SanDisk, Lam Lead Advancers

Semiconductor names climb while select biotech and small-cap listings drop sharply amid company-specific headlines

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
SNDK LRCX MRVL AMAT COST

Equity markets showed differentiated moves Thursday, with several semiconductor and technology-related stocks advancing strongly while certain biotech and small-cap names posted steep declines. Notable gainers included SanDisk and Lam Research, while Ionis Pharmaceuticals and a handful of smaller issuers recorded double-digit losses. The market action spanned mega-cap to small-cap segments and reflected company-specific developments such as trial results, production agreements, sales reports and capital raises.

Stocks Swing Across Market Caps as SanDisk, Lam Lead Advancers
SNDK LRCX MRVL AMAT COST
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Semiconductor and technology-related names led gains among mega- and large-cap stocks, with SanDisk up 12.28% and Lam Research up 6.95%.
  • Company-specific developments drove volatility: Ionis’ failed trial and Gloo’s priced offering corresponded with sharp declines, while production orders and site acquisitions supported advances for other firms.
  • Movements spanned all market-cap segments from mega-caps to small-caps, illustrating sector and capitalization dispersion in intraday trading.

Trading on Thursday produced a mix of pronounced gains and losses across market-cap segments. Activity was driven by company-level announcements and earnings-related data rather than a single market catalyst, producing winners and losers from mega-cap technology to small-cap biopharma.


Mega-cap highlights (Market Cap: $200B+)

  • SanDisk Corp-Exch (SNDK) climbed 12.28%.
  • Lam Research Corp (LRCX) was up 6.95%.
  • Marvell Technology Group Ltd (MRVL) gained 6.79%.
  • Applied Matls Inc (AMAT) rose 5.17%.
  • Costco Whsl Corp New (COST) fell 4.49% - the company reported June net sales of $29.24 billion, an increase of 10.6% year-over-year.

Large-cap movers (Market Cap: $10B-$200B)

  • Isis Pharma (IONS) declined 23.74% after its eplontersen failed to meet the primary endpoint in a heart disease trial.
  • Cerebras Systems Inc (CBRS) rose 10.71% as Flex and Cerebras expand AI system production in California.
  • Amkor Technology (AMKR) increased 9.4%.
  • Entegris Inc. (ENTG) climbed 8.11%.

Mid-cap action (Market Cap: $2B-$10B)

  • 10X Genomics Inc (TXG) advanced 12.75%.
  • Aehr Test Systems (AEHR) rose 12.62% after receiving a silicon photonics production order.
  • Marathon Pa (MARA) gained 9.61% following the acquisition of a Texas site with up to 2 GW power capacity.
  • Chenghe Acquisition II (PLBL) fell 17.4%.

Small-cap movers (Market Cap: $300M-$2B)

  • First Tracks Biotherapeutics (TRAX) jumped 49.69%.
  • Zafgen Inc (LRMR) increased 17.59%.
  • Bull Horns (ZSQR) rose 15.63%.
  • Helen of Troy Ltd (HELE) gained 14.88%.
  • East Stone Acquisition Corp (AIIO) fell 15.4% and Legato Merger III (ENRD) dropped 15.09%.
  • Gloo Holdings Ltd (GLOO) declined 23.62% after pricing a public offering of 7 million shares at $3.25 each.

The session underscored how discrete operational updates, trial outcomes, production deals and capital market activity can produce sharp moves in individual equities across capitalization ranges. Semiconductor and equipment names recorded notable strength, while biotech trial setbacks and financing actions weighed on selected issuers.

Market context and implications

  • Sector dispersion was evident - technology and semiconductor-related firms were among the day's strongest performers, while certain healthcare and small-cap stocks experienced steep losses.
  • Company-specific news, such as clinical trial results and capital raises, drove several of the larger percentage moves rather than broad macro developments.

Further information

This report summarizes the largest reported percentage movers across market-cap brackets for the trading day. The figures above reflect individual stock performance tied to company disclosures and announced developments.

Risks

  • Clinical trial failures can produce steep selloffs in biotechnology and healthcare stocks - exemplified by Ionis’ 23.74% decline after eplontersen failed its primary endpoint, impacting healthcare sector sentiment.
  • Capital markets activity such as public offerings can pressure small-cap share prices - seen with Gloo Holdings pricing 7 million shares at $3.25 each and a subsequent 23.62% drop, affecting small-cap financing dynamics.
  • Concentrated, company-specific news can generate heightened volatility across market caps, increasing short-term risk for traders and investors in technology, semiconductor, and biopharma sectors.

More from Stock Markets

Goldman Tightens Rules, Bans Staff From Most Prediction-Market Bets Jul 9, 2026 Mizuho Raises Rating on Five Below, Cites Valuation Pullback and Social Media Momentum Jul 9, 2026 Musk Names Anthropic the Current Leader in AI, Citing Model Performance Jul 9, 2026 Oracle weathers S&P downgrade but faces mounting AI-driven capital demands Jul 9, 2026 Energy assessments and trader positioning reports set to shape markets on Friday Jul 9, 2026